Theodore Chow, MD
Cardiac Electrophysiology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 10 carriers
- Office
- 1
Offices
1 location · T Chow Cardiology and Electrophysiology Medical Office · 2 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
35 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chow’s office at (408) 240-5960 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Aetna Medicare Eagle (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Aetna Medicare Enhanced (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C53436 · Current
Licensed to practise in California · since 2008 · expires 2028-01-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$1,303,533
Medicare paid this office $1,303,533 for 590 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 188 | $323,156 | $1,701 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 191 | $169,997 | $442 |
| Insertion of heart rhythm monitor under skin | 33 | $165,069 | $5,002 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 140 | $150,919 | $980 |
| Return visit (30+ min) | 341 | $112,982 | $129 |
See all 39 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 188 | $323,156 | $1,701 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 191 | $169,997 | $442 |
| Insertion of heart rhythm monitor under skin | 33 | $165,069 | $5,002 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 140 | $150,919 | $980 |
| Return visit (30+ min) | 341 | $112,982 | $129 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 207 | $47,911 | $218 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 62 | $30,998 | $116 |
| Programming of dual lead pacemaker system | 154 | $25,678 | $85 |
| Ultrasound of both sides of head and neck blood flow | 88 | $19,603 | $220 |
| New patient visit (45+ min) | 97 | $16,026 | $165 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 198 | $15,639 | $78 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 29 | $15,179 | $53 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 28 | $14,737 | $57 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 32 | $13,086 | $409 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 149 | $12,459 | $27 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 160 | $12,002 | $25 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 29 | $11,633 | $41 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 144 | $11,609 | $73 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 12 | $10,195 | $850 |
| Programming of cardiac rhythm monitor system | 52 | $8,861 | $66 |
| Injection of drug or substance into vein | 198 | $8,439 | $42 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 26 | $8,351 | $65 |
| New patient visit (60+ min) | 33 | $7,133 | $216 |
| Long return visit (40+ min) | 34 | $6,898 | $182 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $6,243 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $5,646 | $113 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 11 | $4,677 | $275 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 71 | $4,623 | $65 |
| Injection, regadenoson, 0.1 mg | 191 | $4,189 | None |
| Short return visit (20+ min) | 41 | $4,087 | $93 |
| Programming of dual lead implantable defibrillator system | 23 | $4,078 | $105 |
| Programming of multiple lead implantable defibrillator system | 19 | $3,997 | $111 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 139 | $3,747 | $24 |
| Short return visit | 12 | $2,536 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 121 | $1,993 | $15 |
| Programming of heart rhythm stimulation after drug infusion | 17 | $1,111 | $65 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $1,018 | $35 |
| Infusion, normal saline solution, 250 cc | 199 | $830 | None |
| Ultrasonic guidance for blood vessel access | 21 | $271 | $13 |
Procedures Medicare counted
| Pacemaker insertion or repair | 28 | More than 77% of doctors who do this |
Who their Medicare patients are
590 Original Medicare patients in 2024. Average age 78 · Under 65 4% · 85 and older 24% · Women 49% · Also on Medicaid 39% · Health risk score 1.67. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 1.8.
Conditions among them: High blood pressure 75% · Coronary heart disease 70% · Atrial fibrillation 57% · Diabetes 47% · Heart failure 42% · Chronic kidney disease 34% · Depression 19% · Cancer 18% · COPD 18% · Stroke 18% · Dementia 14%.
The office billed $3,319,685, Medicare allowed $1,621,014 and paid $1,303,533; for 8,671 services of 77 kinds; $5,092 of it was for drugs given in the office and $1,298,441 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 590 | 8,671 | 78 | 1.67 | $3,319,685 | $1,303,533 |
| 2023 | 600 | 12,391 | 78 | 1.77 | $3,252,719 | $1,186,945 |
| 2022 | 589 | 16,627 | 78 | 1.85 | $3,207,820 | $1,162,365 |
| 2021 | 584 | 14,632 | 77 | 2.22 | $3,204,525 | $1,138,750 |
| 2020 | 514 | 12,438 | 77 | 2.20 | $2,869,746 | $1,017,866 |
| 2019 | 594 | 15,647 | 76 | 1.89 | $3,124,750 | $1,111,002 |
| 2018 | 641 | 15,465 | 76 | 2.00 | $2,272,825 | $861,791 |
| 2017 | 421 | 3,994 | 76 | 2.12 | $996,980 | $270,021 |
| 2016 | 448 | 2,669 | 76 | 2.02 | $1,137,454 | $270,886 |
| 2015 | 359 | 1,980 | 76 | 2.04 | $902,975 | $211,056 |
| 2014 | 304 | 1,994 | 76 | 1.94 | $867,113 | $197,074 |
| 2013 | 303 | 2,027 | 76 | 1.85 | $809,569 | $188,312 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 48 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 172 | $278,399 | $1,600 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 172 | $145,257 | $417 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 130 | $138,326 | $954 |
| Insertion of heart rhythm monitor under skin | 20 | $99,140 | $4,957 |
| Return visit (30+ min) | 316 | $97,868 | $114 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 222 | $50,288 | $203 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 114 | $45,618 | $65 |
| Programming of dual lead pacemaker system | 151 | $19,858 | $78 |
| Injection, regadenoson, 0.1 mg | 114 | $18,537 | None |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 36 | $17,704 | $52 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 36 | $16,776 | $48 |
| New patient visit (45+ min) | 103 | $15,249 | $148 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 38 | $15,032 | $396 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 36 | $14,610 | $38 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 196 | $14,250 | $72 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 15 | $12,410 | $827 |
| Ultrasound of both sides of head and neck blood flow | 53 | $10,917 | $206 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 151 | $10,606 | $25 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 23 | $10,500 | $457 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 80 | $9,924 | $120 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 126 | $9,770 | $27 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 59 | $9,170 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $8,995 | $110 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 115 | $8,851 | $70 |
| Injection of drug or substance into vein | 196 | $8,009 | $40 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 14 | $7,616 | $544 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 57 | $6,904 | $22 |
| Programming of cardiac rhythm monitor system | 56 | $6,852 | $59 |
| New patient visit (60+ min) | 29 | $5,812 | $200 |
| Long return visit (40+ min) | 33 | $5,754 | $164 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 14 | $5,627 | $268 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 91 | $5,176 | $56 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 23 | $4,400 | $96 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 14 | $3,751 | $268 |
| Short return visit | 12 | $3,523 | $57 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 133 | $3,446 | $23 |
| Programming of dual lead implantable defibrillator system | 21 | $3,183 | $96 |
| Short return visit (20+ min) | 31 | $2,847 | $86 |
| Programming of multiple lead implantable defibrillator system | 15 | $2,568 | $107 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 27 | $2,179 | $32 |
| Programming of heart rhythm stimulation after drug infusion | 27 | $2,162 | $80 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 123 | $1,753 | $14 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 73 | $1,189 | None |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 14 | $1,013 | $72 |
| Infusion, normal saline solution, 250 cc | 196 | $780 | None |
| Blood test, clotting time | 11 | $344 | $4 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 25 | $275 | $11 |
| Ultrasonic guidance for blood vessel access | 13 | $162 | $12 |
2022: 47 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 148 | $244,171 | $1,596 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 129 | $152,971 | $1,013 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 148 | $126,691 | $414 |
| Insertion of heart rhythm monitor under skin | 19 | $99,705 | $5,248 |
| Return visit (30+ min) | 281 | $91,817 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 222 | $53,509 | $203 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 123 | $21,327 | $25 |
| Programming of dual lead pacemaker system | 140 | $20,875 | $82 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 38 | $20,520 | $56 |
| Ultrasound of both sides of head and neck blood flow | 99 | $20,468 | $207 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 40 | $19,157 | $38 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 39 | $19,131 | $491 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 45 | $18,606 | $413 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 40 | $18,427 | $48 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $13,674 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 183 | $13,334 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 103 | $13,152 | $122 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 13 | $12,785 | $983 |
| Long return visit (40+ min) | 62 | $12,203 | $163 |
| New patient visit (45+ min) | 84 | $12,069 | $144 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 135 | $11,635 | $71 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 71 | $10,695 | $23 |
| Programming of cardiac rhythm monitor system | 68 | $10,441 | $64 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 58 | $8,708 | $22 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 129 | $8,380 | $26 |
| New patient visit (60+ min) | 40 | $7,876 | $197 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 109 | $7,574 | $27 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 35 | $6,734 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 102 | $6,697 | $63 |
| Injection of drug or substance into vein | 117 | $5,013 | $42 |
| Short return visit | 19 | $4,905 | $52 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 22 | $4,675 | $195 |
| Short return visit (20+ min) | 46 | $4,373 | $89 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 129 | $3,576 | $24 |
| Removal and replacement of dual lead permanent pacemaker | 13 | $3,534 | $272 |
| Programming of multiple lead implantable defibrillator system | 16 | $3,487 | $112 |
| Programming of dual lead implantable defibrillator system | 24 | $3,474 | $102 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 168 | $2,665 | None |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 21 | $1,665 | $33 |
| Programming of heart rhythm stimulation after drug infusion | 14 | $1,437 | $103 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 99 | $1,364 | $13 |
| Infusion, normal saline solution, 250 cc | 186 | $770 | None |
| Programming of dual lead pacemaker system | 17 | $748 | $36 |
| Removal of heart rhythm monitor from under the skin | 13 | $600 | $46 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 32 | $570 | $14 |
| Blood test, clotting time | 17 | $497 | $4 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 25 | $290 | $11 |
2021: 50 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 115 | $194,527 | $1,663 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 148 | $149,743 | $805 |
| Insertion of heart rhythm monitor under skin | 24 | $140,002 | $5,833 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 115 | $99,229 | $424 |
| Return visit (30+ min) | 251 | $86,975 | $120 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 177 | $42,330 | $212 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 124 | $23,443 | $25 |
| Ultrasound of both sides of head and neck blood flow | 101 | $22,309 | $219 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 38 | $21,995 | $69 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 39 | $21,306 | $40 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 39 | $20,428 | $511 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 39 | $18,429 | $50 |
| Programming of dual lead pacemaker system | 123 | $17,289 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 89 | $16,730 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 109 | $14,685 | $126 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 146 | $13,986 | $76 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 35 | $13,981 | $399 |
| Long return visit (40+ min) | 69 | $13,268 | $172 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 155 | $11,074 | $70 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 61 | $10,860 | $23 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 20 | $10,808 | $540 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 64 | $10,754 | $24 |
| Insertion of implantable defibrillator system | 15 | $10,696 | $713 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 14 | $10,494 | $750 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 124 | $9,817 | $27 |
| Programming of cardiac rhythm monitor system | 61 | $8,889 | $56 |
| New patient visit (45+ min) | 58 | $8,712 | $150 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $7,629 | $63 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 39 | $7,616 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,583 | $172 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 97 | $7,387 | $27 |
| Short return visit (20+ min) | 66 | $7,135 | $88 |
| New patient visit (60+ min) | 32 | $6,653 | $208 |
| Short return visit | 23 | $5,930 | $53 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 22 | $5,848 | $266 |
| Programming of dual lead implantable defibrillator system | 31 | $5,719 | $97 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 148 | $4,486 | $24 |
| Programming of heart rhythm stimulation after drug infusion | 30 | $4,255 | $133 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 33 | $3,709 | $106 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 27 | $2,834 | $32 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 130 | $2,564 | None |
| Programming of multiple lead implantable defibrillator system | 11 | $2,388 | $99 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 11 | $1,282 | $117 |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 27 | $670 | $15 |
| Infusion, normal saline solution, 250 cc | 153 | $651 | None |
| Ultrasonic guidance for blood vessel access | 43 | $585 | $13 |
| Programming of dual lead pacemaker system | 11 | $580 | $36 |
| Blood test, clotting time | 16 | $528 | $4 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 28 | $384 | $14 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $277 | $12 |
2020: 50 services
| Insertion of heart rhythm monitor under skin | 38 | $214,607 | $5,648 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 108 | $181,667 | $1,667 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 127 | $122,645 | $786 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 109 | $92,424 | $420 |
| Return visit (30+ min) | 255 | $72,878 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 184 | $46,343 | $214 |
| Ultrasound of both sides of head and neck blood flow | 83 | $17,820 | $212 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 109 | $15,886 | $24 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $13,434 | $517 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 125 | $12,616 | $82 |
| Programming of dual lead pacemaker system | 106 | $11,984 | $67 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 20 | $10,859 | $543 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 58 | $10,359 | $24 |
| Long return visit (40+ min) | 65 | $10,034 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,834 | $182 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 133 | $9,608 | $71 |
| New patient visit (45+ min) | 64 | $8,638 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $8,308 | $94 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 31 | $8,278 | $69 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 30 | $7,927 | $40 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 55 | $7,282 | $25 |
| Insertion of pacemaker and lower heart chamber electrode | 18 | $6,917 | $384 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 52 | $6,667 | $126 |
| Programming of cardiac rhythm monitor system | 55 | $6,593 | $51 |
| New patient visit (60+ min) | 35 | $6,529 | $187 |
| Short return visit | 26 | $6,153 | $44 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 106 | $6,145 | $27 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 31 | $6,103 | $51 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 87 | $6,000 | $69 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 26 | $5,091 | $98 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 82 | $4,880 | $28 |
| Short return visit (20+ min) | 55 | $4,471 | $70 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 130 | $3,939 | $25 |
| Programming of heart rhythm stimulation after drug infusion | 24 | $3,611 | $144 |
| Programming of dual lead implantable defibrillator system | 27 | $3,509 | $84 |
| Removal and replacement of dual lead permanent pacemaker | 12 | $3,147 | $262 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 27 | $2,885 | $103 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 121 | $2,623 | None |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 50 | $2,560 | $36 |
| Programming of multiple lead implantable defibrillator system | 14 | $2,292 | $96 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 59 | $684 | $11 |
| Anticoagulant management of patient taking warfarin | 19 | $607 | $11 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 30 | $596 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 37 | $595 | $16 |
| Programming of dual lead pacemaker system | 14 | $553 | $37 |
| Infusion, normal saline solution, 250 cc | 132 | $528 | None |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 31 | $443 | $14 |
| Ultrasonic guidance for blood vessel access | 29 | $386 | $13 |
| Blood test, clotting time | 17 | $305 | $4 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $240 | $18 |
2019: 50 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 121 | $189,339 | $1,539 |
| Insertion of heart rhythm monitor under skin | 34 | $183,772 | $5,405 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 144 | $148,221 | $760 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 125 | $102,884 | $408 |
| Return visit (30+ min) | 262 | $82,628 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 187 | $43,090 | $205 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 43 | $22,108 | $514 |
| Long return visit (40+ min) | 143 | $21,895 | $124 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 21 | $20,037 | $954 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $19,527 | $176 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 22 | $17,035 | $710 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | $17,012 | $500 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 155 | $16,832 | $79 |
| Ultrasound of both sides of head and neck blood flow | 74 | $15,668 | $209 |
| Programming of dual lead pacemaker system | 129 | $14,513 | $60 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 32 | $13,654 | $427 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 46 | $12,412 | $253 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 155 | $10,943 | $68 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 72 | $10,304 | $22 |
| Insertion of implantable defibrillator system | 12 | $9,194 | $766 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $8,459 | $93 |
| New patient visit (60+ min) | 43 | $8,070 | $188 |
| New patient visit (45+ min) | 54 | $7,750 | $144 |
| Programming of heart rhythm stimulation after drug infusion | 52 | $7,317 | $138 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 62 | $6,686 | $101 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 30 | $6,107 | $95 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 90 | $5,460 | $26 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 77 | $5,401 | $67 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 110 | $5,393 | $12 |
| Programming of cardiac rhythm monitor system | 48 | $5,284 | $47 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 155 | $5,031 | $23 |
| Short return visit (20+ min) | 62 | $4,825 | $67 |
| Programming of dual lead implantable defibrillator system | 31 | $4,818 | $76 |
| Insertion of pacemaker and lower heart chamber electrode | 12 | $4,719 | $393 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 132 | $4,670 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 72 | $4,534 | $26 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 46 | $3,760 | $22 |
| Removal and replacement of dual lead permanent pacemaker | 11 | $3,284 | $299 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 24 | $3,179 | $127 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 158 | $2,881 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $2,603 | $22 |
| Programming of multiple lead implantable defibrillator system | 15 | $2,441 | $84 |
| Short return visit | 32 | $2,100 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,073 | $122 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 20 | $1,367 | $37 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 112 | $1,297 | $11 |
| Ultrasonic guidance for blood vessel access | 81 | $1,102 | $13 |
| Insertion of heart rhythm monitor under skin | 13 | $937 | $72 |
| Infusion, normal saline solution, 250 cc | 151 | $581 | None |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 20 | $272 | $14 |
2018: 44 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 123 | $192,833 | $1,530 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 122 | $134,496 | $787 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 123 | $84,062 | $339 |
| Return visit (30+ min) | 249 | $64,066 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 158 | $40,075 | $209 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 26 | $23,552 | $906 |
| Long return visit (40+ min) | 137 | $20,769 | $124 |
| New patient visit (60+ min) | 120 | $20,685 | $172 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 46 | $18,703 | $407 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 24 | $16,762 | $698 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $16,185 | $180 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 29 | $13,751 | $474 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 49 | $13,328 | $272 |
| Short return visit (20+ min) | 82 | $12,797 | $68 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $12,594 | $504 |
| Insertion of implantable defibrillator system | 14 | $10,568 | $755 |
| Programming of dual lead pacemaker system | 93 | $10,035 | $54 |
| New patient visit (45+ min) | 69 | $9,659 | $140 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 141 | $9,554 | $65 |
| Ultrasound of both sides of head and neck blood flow | 44 | $9,357 | $203 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 83 | $8,242 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | $8,060 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $7,022 | $94 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 56 | $6,975 | $22 |
| Programming of heart rhythm stimulation after drug infusion | 46 | $6,203 | $135 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 83 | $5,179 | $27 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 52 | $5,177 | $100 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 134 | $5,170 | None |
| Short return visit | 46 | $4,902 | $43 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 193 | $4,706 | $16 |
| Programming of dual lead implantable defibrillator system | 34 | $4,250 | $71 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 127 | $4,039 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 59 | $3,612 | $26 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 16 | $3,053 | $95 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 26 | $2,892 | $52 |
| Implantation patient-activated heart monitoring device | 18 | $2,891 | $161 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 29 | $2,740 | $23 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 22 | $2,710 | $123 |
| Remote evaluations of implantable heart and blood vessel monitor or loop recorder system with technician analysis, review, and report, up to 30 days | 63 | $2,191 | $13 |
| Programming of cardiac rhythm monitor system | 21 | $1,421 | $38 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 65 | $740 | $11 |
| Ultrasonic guidance for blood vessel access | 52 | $640 | $12 |
| Infusion, normal saline solution, 250 cc | 143 | $521 | None |
| Programming of single, dual, or multiple lead or leadless pacemaker system before or after surgery | 16 | $211 | $13 |
2017: 34 services
| Return visit (30+ min) | 263 | $89,418 | $94 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 13 | $19,246 | $1,480 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $11,592 | $93 |
| Programming of dual lead pacemaker system | 95 | $11,554 | $51 |
| Long return visit (40+ min) | 72 | $11,377 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $10,852 | $181 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 19 | $6,752 | $355 |
| New patient visit (45+ min) | 51 | $6,669 | $131 |
| New patient visit (60+ min) | 37 | $6,474 | $175 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 13 | $6,319 | $486 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 12 | $6,102 | $509 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 13 | $5,950 | $229 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $5,858 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 97 | $5,835 | $57 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 21 | $5,453 | $260 |
| Programming of cardiac rhythm monitor system | 26 | $2,810 | $36 |
| Programming of dual lead implantable defibrillator system | 20 | $2,772 | $68 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 11 | $1,916 | $87 |
| Programming of multiple lead implantable defibrillator system | 12 | $1,857 | $81 |
| Programming of heart rhythm stimulation after drug infusion | 13 | $1,815 | $140 |
| Short return visit (20+ min) | 22 | $1,799 | $69 |
| Implantation patient-activated heart monitoring device | 13 | $1,790 | $138 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 25 | $1,760 | $70 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 16 | $1,749 | $103 |
| Blood test, clotting time | 36 | $1,009 | $5 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 20 | $691 | $24 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 19 | $641 | $28 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 21 | $576 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $550 | $31 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 23 | $461 | $19 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 16 | $375 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | $345 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 23 | $310 | $13 |
| Infusion, normal saline solution, 250 cc | 25 | $86 | None |
2016: 29 services
| Return visit (30+ min) | 230 | $78,160 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 95 | $23,796 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 70 | $16,170 | $225 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $11,176 | $180 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 18 | $9,997 | $555 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 76 | $9,598 | $121 |
| Programming of dual lead pacemaker system | 83 | $9,405 | $51 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 16 | $8,886 | $555 |
| New patient visit (45+ min) | 58 | $8,375 | $144 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 139 | $8,366 | $57 |
| Long return visit (40+ min) | 51 | $8,179 | $126 |
| New patient visit (60+ min) | 42 | $7,696 | $183 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 28 | $7,513 | $268 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $7,246 | $453 |
| Programming of heart rhythm stimulation after drug infusion | 20 | $2,754 | $138 |
| Programming of heart rhythm stimulation after drug infusion | 19 | $2,616 | $138 |
| Programming of dual lead implantable defibrillator system | 18 | $2,239 | $72 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 22 | $2,228 | $101 |
| Programming of cardiac rhythm monitor system | 19 | $2,166 | $40 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 21 | $2,127 | $101 |
| Blood test, clotting time | 37 | $1,407 | $5 |
| Implantation patient-activated heart monitoring device | 12 | $1,201 | $100 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 73 | $1,098 | $15 |
| Short return visit (20+ min) | 14 | $961 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 45 | $921 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 45 | $601 | $13 |
| Ultrasound of heart, follow-up | 14 | $348 | $23 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $86 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $35 | $3 |
2015: 22 services
| Return visit (30+ min) | 185 | $51,666 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $21,154 | $218 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 30 | $16,420 | $530 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $13,225 | $93 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 25 | $10,389 | $416 |
| Programming of dual lead pacemaker system | 62 | $6,673 | $50 |
| Long return visit (40+ min) | 39 | $6,542 | $128 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 50 | $6,477 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $6,246 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,980 | $181 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 18 | $4,804 | $267 |
| New patient visit (45+ min) | 32 | $4,753 | $149 |
| New patient visit (60+ min) | 26 | $4,634 | $178 |
| Programming of heart rhythm stimulation after drug infusion | 30 | $4,327 | $140 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 38 | $3,994 | $102 |
| Short return visit (20+ min) | 35 | $2,478 | $60 |
| Programming of multiple lead implantable defibrillator system | 11 | $1,653 | $79 |
| Programming of cardiac rhythm monitor system | 12 | $1,617 | $39 |
| Blood test, clotting time | 28 | $1,179 | $5 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $985 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 35 | $683 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 35 | $445 | $13 |
2014: 29 services
| Return visit (30+ min) | 193 | $54,661 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 100 | $24,667 | $226 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 19 | $10,594 | $558 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 31 | $8,623 | $278 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 11 | $7,965 | $724 |
| Programming of dual lead pacemaker system | 63 | $6,004 | $53 |
| New patient visit (45+ min) | 40 | $5,722 | $143 |
| Short return visit (20+ min) | 58 | $5,071 | $61 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 13 | $4,387 | $337 |
| New patient visit (60+ min) | 23 | $4,165 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,697 | $92 |
| External ekg recording for more than 48 hours up to 21 days with analysis, report, review and interpretation | 17 | $3,628 | $191 |
| Programming of heart rhythm stimulation after drug infusion | 22 | $3,300 | $138 |
| Long return visit (40+ min) | 20 | $2,818 | $128 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 46 | $2,756 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,518 | $180 |
| New patient visit (30+ min) | 22 | $2,185 | $99 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 20 | $2,124 | $101 |
| Analysis and report of external ekg recording for more than 48 hours up to 21 days | 12 | $1,780 | $148 |
| Blood test, clotting time | 42 | $1,741 | $5 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,461 | $122 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,339 | $89 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 74 | $1,199 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 30 | $596 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 30 | $391 | $13 |
| Electrocardiogram (ecg) 2-day continuous | 12 | $292 | $24 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 12 | $291 | $24 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 12 | $274 | $23 |
| External ekg recording for more than 48 hours up to 21 days | 12 | $198 | $17 |
2013: 32 services
| Return visit (30+ min) | 190 | $45,357 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 116 | $14,057 | $115 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 11 | $10,104 | $919 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 22 | $9,710 | $441 |
| New patient visit (45+ min) | 66 | $9,327 | $141 |
| Short return visit (20+ min) | 84 | $8,121 | $60 |
| Insertion of catheters for recording and pacing of right heart chambers rhythm and induction of abnormal rhythm | 13 | $6,768 | $521 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 18 | $6,443 | $322 |
| New patient visit (60+ min) | 32 | $5,486 | $171 |
| Programming of dual lead pacemaker system | 59 | $5,346 | $52 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 34 | $5,255 | $155 |
| Long return visit (40+ min) | 30 | $4,230 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,856 | $88 |
| Analysis and report of external ekg recording for more than 48 hours up to 21 days | 12 | $2,198 | $183 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $2,099 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 100 | $1,920 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,814 | $165 |
| Programming of dual lead implantable defibrillator system | 15 | $1,807 | $67 |
| Blood test, clotting time | 45 | $1,627 | $5 |
| Programming of multiple lead implantable defibrillator system | 12 | $1,486 | $78 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,422 | $119 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 12 | $1,159 | $97 |
| Short return visit | 21 | $957 | $34 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 13 | $886 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $812 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 28 | $575 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 33 | $445 | $13 |
| Electrocardiogram (ecg) 2-day continuous | 17 | $442 | $26 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 12 | $280 | $23 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 13 | $268 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 13 | $152 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 15 | $108 | $7 |
Medicaid work
$4,261 in 2024
Medicaid paid $4,261 for 631 billed services this clinician did in 2024, up to 54 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 168 | $3,014 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 78 | $478 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 80 | $394 |
| Return visit (30+ min) | 281 | $375 |
| XTRNL MOBILE CV TELEMETRY W/I&REPORT 30 DAYS | 12 | $0 |
| External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional | 12 | $0 |
| 2024 | 631 | 6 | 54 | $4,261 |
| 2023 | 1,122 | 13 | 60 | $7,686 |
| 2022 | 788 | 9 | 61 | $6,842 |
| 2021 | 604 | 6 | 43 | $2,736 |
| 2020 | 366 | 5 | 31 | $2,952 |
| 2019 | 151 | 5 | 18 | $991 |
| 2018 | 42 | 3 | 15 | $376 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 264 | $5,438 |
| Return visit (30+ min) | 353 | $853 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 91 | $416 |
| CARDIOVASCULAR STRESS TEST | 78 | $355 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 45 | $182 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 129 | $123 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 26 | $112 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug | 12 | $112 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 40 | $48 |
| XTRNL MOBILE CV TELEMETRY W/I&REPORT 30 DAYS | 12 | $24 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 45 | $18 |
| Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system | 14 | $6 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 273 | $5,656 |
| Return visit (30+ min) | 321 | $772 |
| Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional | 81 | $151 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 24 | $144 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 20 | $94 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 33 | $18 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 12 | $7 |
| Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system | 12 | $0 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 12 | $0 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 165 | $1,777 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 62 | $368 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 44 | $300 |
| Return visit (30+ min) | 294 | $237 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 26 | $55 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 13 | $0 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 96 | $2,151 |
| Return visit (30+ min) | 227 | $505 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 13 | $191 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 15 | $80 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 15 | $26 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 18 | $388 |
| Return visit (30+ min) | 66 | $268 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional | 28 | $241 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, leadless pacemaker system, or implantable defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 14 | $69 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 25 | $24 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $307 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $69 |
| Return visit (30+ min) | 15 | $0 |
Drugs they prescribed that Part D paid
$1,218,931
Pharmacies billed $1,218,931 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,286) in 2024. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 0%.
3,782 generic and 1,504 brand-name prescriptions · $1,218,931 in drug cost · 129 antibiotic prescriptions to 119 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 508 | $391,554 | $771 |
| Farxiga | 254 | $174,901 | $689 |
| Jardiance | 247 | $167,299 | $677 |
| Xarelto | 139 | $121,714 | $876 |
| Entresto | 130 | $109,422 | $842 |
See all 43 drugs
| Eliquis | 508 | $391,554 | $771 |
| Farxiga | 254 | $174,901 | $689 |
| Jardiance | 247 | $167,299 | $677 |
| Xarelto | 139 | $121,714 | $876 |
| Entresto | 130 | $109,422 | $842 |
| Camzyos | 13 | $88,024 | $6,771 |
| Repatha Sureclick | 83 | $50,678 | $611 |
| Multaq | 46 | $43,162 | $938 |
| Metoprolol | 655 | $8,345 | $13 |
| Vascepa | 17 | $7,912 | $465 |
| Propafenone Hcl Er | 21 | $5,194 | $247 |
| Amiodarone | 231 | $4,340 | $19 |
| Atorvastatin | 395 | $3,783 | $10 |
| Dabigatran Etexilate | 13 | $3,651 | $281 |
| Digoxin | 50 | $2,958 | $59 |
| Losartan | 305 | $2,572 | $8 |
| Sotalol | 141 | $2,430 | $17 |
| Midodrine | 51 | $2,315 | $45 |
| Isosorbide Mononitrate Er | 117 | $1,690 | $14 |
| Propafenone | 25 | $1,389 | $56 |
| Spironolactone | 221 | $1,314 | $6 |
| Hydralazine | 82 | $1,199 | $15 |
| Warfarin | 77 | $1,190 | $15 |
| Carvedilol | 125 | $1,181 | $9 |
| Clopidogrel | 98 | $1,038 | $11 |
| Amlodipine Besylate | 201 | $978 | $5 |
| Nifedipine Er | 31 | $781 | $25 |
| Metoprolol | 80 | $649 | $8 |
| Flecainide Acetate | 39 | $641 | $16 |
| Rosuvastatin | 58 | $606 | $10 |
| Eplerenone | 11 | $592 | $54 |
| Chlorthalidone | 79 | $562 | $7 |
| Lisinopril | 70 | $554 | $8 |
| Bumetanide | 42 | $509 | $12 |
| Furosemide | 90 | $424 | $5 |
| Cephalexin | 119 | $345 | $3 |
| Potassium Chloride | 53 | $342 | $6 |
| Diltiazem | 20 | $309 | $15 |
| Hydrochlorothiazide | 85 | $270 | $3 |
| Atenolol | 51 | $241 | $5 |
| Pravastatin | 15 | $186 | $12 |
| Clonidine | 23 | $95 | $4 |
| Simvastatin | 11 | $86 | $8 |
Year by year
| 2024 | 5,286 | 547 | 0% (0) | 28% | $1,218,931 |
| 2023 | 4,315 | 469 | 0% (0) | None | $861,494 |
| 2022 | 3,370 | 380 | None | 21% | $593,724 |
| 2021 | 2,786 | 308 | 0% (0) | 21% | $439,591 |
| 2020 | 2,807 | 288 | 0% (0) | 21% | $357,040 |
| 2019 | 2,895 | 303 | None | 15% | $264,637 |
| 2018 | 1,846 | 218 | None | 14% | $127,757 |
| 2017 | 1,605 | 180 | None | 18% | $108,033 |
| 2016 | 1,179 | 139 | None | 16% | $56,496 |
| 2015 | 927 | 113 | None | 17% | $56,145 |
| 2014 | 917 | 116 | None | 16% | $57,660 |
| 2013 | 911 | 107 | None | 16% | $51,195 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 40 drugs
| Eliquis | 495 | $396,586 | $801 |
| Entresto | 126 | $105,080 | $834 |
| Xarelto | 119 | $99,218 | $834 |
| Jardiance | 74 | $59,808 | $808 |
| Farxiga | 56 | $39,625 | $708 |
| Repatha Sureclick | 50 | $34,048 | $681 |
| Multaq | 16 | $15,962 | $998 |
| Metoprolol | 597 | $11,343 | $19 |
| Amiodarone | 227 | $8,146 | $36 |
| Dabigatran Etexilate | 11 | $6,695 | $609 |
| Losartan | 266 | $3,911 | $15 |
| Sotalol | 149 | $3,795 | $25 |
| Propafenone Hcl Er | 19 | $3,663 | $193 |
| Atorvastatin | 252 | $3,534 | $14 |
| Midodrine | 42 | $2,972 | $71 |
| Isosorbide Mononitrate Er | 108 | $2,569 | $24 |
| Flecainide Acetate | 37 | $2,388 | $65 |
| Propafenone | 21 | $2,162 | $103 |
| Carvedilol | 134 | $2,115 | $16 |
| Warfarin | 108 | $1,895 | $18 |
| Hydralazine | 80 | $1,799 | $22 |
| Clopidogrel | 107 | $1,591 | $15 |
| Digoxin | 53 | $1,586 | $30 |
| Amlodipine Besylate | 179 | $1,504 | $8 |
| Diltiazem 24hr Er (Cd) | 24 | $1,439 | $60 |
| Lisinopril | 85 | $1,397 | $16 |
| Potassium Chloride | 52 | $1,314 | $25 |
| Spironolactone | 83 | $951 | $11 |
| Furosemide | 125 | $874 | $7 |
| Metoprolol | 67 | $742 | $11 |
| Diltiazem | 25 | $737 | $29 |
| Hydrochlorothiazide | 143 | $575 | $4 |
| Cephalexin | 103 | $418 | $4 |
| Atenolol | 29 | $324 | $11 |
| Clonidine | 31 | $251 | $8 |
| Simvastatin | 17 | $221 | $13 |
| Fenofibrate | 12 | $219 | $18 |
| Pantoprazole | 14 | $215 | $15 |
| Rosuvastatin | 12 | $167 | $14 |
| Levofloxacin | 13 | $62 | $5 |
2022: 39 drugs
| Eliquis | 415 | $312,945 | $754 |
| Entresto | 81 | $61,132 | $755 |
| Xarelto | 60 | $59,315 | $989 |
| Repatha Sureclick | 52 | $36,411 | $700 |
| Jardiance | 19 | $15,683 | $825 |
| Metoprolol | 396 | $6,832 | $17 |
| Amiodarone | 208 | $6,280 | $30 |
| Propafenone Hcl Er | 18 | $5,156 | $286 |
| Sotalol | 134 | $3,514 | $26 |
| Diltiazem 24hr Er (Cd) | 43 | $2,419 | $56 |
| Digoxin | 70 | $2,290 | $33 |
| Atorvastatin | 169 | $2,153 | $13 |
| Flecainide Acetate | 36 | $2,143 | $60 |
| Isosorbide Mononitrate Er | 114 | $1,973 | $17 |
| Clopidogrel | 128 | $1,842 | $14 |
| Losartan | 137 | $1,547 | $11 |
| Warfarin | 95 | $1,539 | $16 |
| Lisinopril | 108 | $1,383 | $13 |
| Midodrine | 18 | $1,362 | $76 |
| Potassium Chloride | 39 | $1,346 | $35 |
| Ranolazine Er | 11 | $1,304 | $119 |
| Hydralazine | 61 | $1,294 | $21 |
| Propafenone | 14 | $1,070 | $76 |
| Carvedilol | 111 | $931 | $8 |
| Furosemide | 90 | $695 | $8 |
| Amlodipine Besylate | 114 | $677 | $6 |
| Diltiazem | 31 | $606 | $20 |
| Diltiazem 24hr Er | 14 | $481 | $34 |
| Hydrochlorothiazide | 118 | $402 | $3 |
| Metoprolol | 58 | $389 | $7 |
| Cephalexin | 104 | $380 | $4 |
| Spironolactone | 34 | $310 | $9 |
| Clonidine | 29 | $291 | $10 |
| Simvastatin | 24 | $272 | $11 |
| Levothyroxine | 15 | $257 | $17 |
| Fenofibrate | 13 | $237 | $18 |
| Rosuvastatin | 12 | $124 | $10 |
| Levofloxacin | 14 | $119 | $8 |
| Atenolol | 15 | $104 | $7 |
2021: 37 drugs
| Eliquis | 388 | $266,612 | $687 |
| Xarelto | 57 | $43,719 | $767 |
| Repatha Sureclick | 34 | $24,099 | $709 |
| Propafenone Hcl Er | 22 | $8,783 | $399 |
| Metoprolol | 335 | $6,838 | $20 |
| Amiodarone | 183 | $4,177 | $23 |
| Midodrine | 31 | $3,243 | $105 |
| Sotalol | 99 | $3,106 | $31 |
| Flecainide Acetate | 31 | $2,306 | $74 |
| Digoxin | 50 | $2,129 | $43 |
| Atorvastatin | 144 | $1,802 | $13 |
| Diltiazem 24hr Er (Cd) | 49 | $1,747 | $36 |
| Isosorbide Mononitrate Er | 90 | $1,711 | $19 |
| Warfarin | 117 | $1,701 | $15 |
| Clopidogrel | 118 | $1,465 | $12 |
| Propafenone | 24 | $1,252 | $52 |
| Losartan | 80 | $898 | $11 |
| Potassium Chloride | 45 | $879 | $20 |
| Diltiazem | 27 | $844 | $31 |
| Lisinopril | 71 | $742 | $10 |
| Carvedilol | 76 | $680 | $9 |
| Dilt-Xr | 12 | $509 | $42 |
| Metoprolol | 74 | $482 | $7 |
| Amlodipine Besylate | 81 | $429 | $5 |
| Diltiazem 24hr Er | 13 | $408 | $31 |
| Furosemide | 96 | $391 | $4 |
| Hydralazine | 29 | $341 | $12 |
| Rosuvastatin | 16 | $321 | $20 |
| Levothyroxine | 21 | $307 | $15 |
| Cephalexin | 66 | $240 | $4 |
| Fenofibrate | 12 | $212 | $18 |
| Ranolazine Er | 11 | $211 | $19 |
| Hydrochlorothiazide | 74 | $200 | $3 |
| Verapamil | 13 | $186 | $14 |
| Clonidine | 21 | $158 | $8 |
| Simvastatin | 16 | $151 | $9 |
| Levofloxacin | 12 | $126 | $10 |
2020: 37 drugs
| Eliquis | 359 | $208,215 | $580 |
| Xarelto | 50 | $32,569 | $651 |
| Propafenone Hcl Er | 22 | $17,712 | $805 |
| Repatha Sureclick | 20 | $17,087 | $854 |
| Pradaxa | 11 | $12,892 | $1,172 |
| Metoprolol | 323 | $6,545 | $20 |
| Sotalol | 127 | $4,811 | $38 |
| Amiodarone | 191 | $4,056 | $21 |
| Midodrine | 28 | $3,306 | $118 |
| Digoxin | 52 | $2,643 | $51 |
| Flecainide Acetate | 30 | $2,613 | $87 |
| Warfarin | 148 | $2,278 | $15 |
| Atorvastatin | 157 | $2,077 | $13 |
| Diltiazem 24hr Er (Cd) | 43 | $1,683 | $39 |
| Isosorbide Mononitrate Er | 83 | $1,627 | $20 |
| Clopidogrel | 108 | $1,383 | $13 |
| Propafenone | 18 | $1,178 | $65 |
| Potassium Chloride | 58 | $1,121 | $19 |
| Rosuvastatin | 23 | $946 | $41 |
| Isosorbide Dinitrate | 17 | $857 | $50 |
| Diltiazem | 29 | $791 | $27 |
| Amlodipine Besylate | 139 | $776 | $6 |
| Furosemide | 119 | $753 | $6 |
| Losartan | 74 | $690 | $9 |
| Carvedilol | 70 | $472 | $7 |
| Lisinopril | 88 | $431 | $5 |
| Cartia Xt | 13 | $423 | $33 |
| Atenolol | 18 | $407 | $23 |
| Dilt-Xr | 12 | $352 | $29 |
| Verapamil | 11 | $339 | $31 |
| Clonidine | 14 | $333 | $24 |
| Metoprolol | 36 | $252 | $7 |
| Hydrochlorothiazide | 75 | $235 | $3 |
| Levofloxacin | 17 | $209 | $12 |
| Hydralazine | 13 | $178 | $14 |
| Cephalexin | 65 | $152 | $2 |
| Simvastatin | 19 | $76 | $4 |
2019: 38 drugs
| Eliquis | 207 | $106,698 | $515 |
| Xarelto | 57 | $32,279 | $566 |
| Pradaxa | 26 | $18,550 | $713 |
| Propafenone Hcl Er | 14 | $11,847 | $846 |
| Brilinta | 17 | $11,836 | $696 |
| Repatha Sureclick | 15 | $11,245 | $750 |
| Metoprolol | 345 | $7,397 | $21 |
| Sotalol | 131 | $3,658 | $28 |
| Warfarin | 188 | $2,834 | $15 |
| Amiodarone | 153 | $2,773 | $18 |
| Midodrine | 30 | $2,709 | $90 |
| Atorvastatin | 140 | $2,136 | $15 |
| Flecainide Acetate | 29 | $2,043 | $70 |
| Clopidogrel | 191 | $1,840 | $10 |
| Isosorbide Mononitrate Er | 127 | $1,836 | $14 |
| Digoxin | 50 | $1,783 | $36 |
| Diltiazem 24hr Er (Cd) | 40 | $1,396 | $35 |
| Digox | 22 | $1,238 | $56 |
| Propafenone | 17 | $1,143 | $67 |
| Isosorbide Dinitrate | 21 | $989 | $47 |
| Cartia Xt | 20 | $956 | $48 |
| Amlodipine Besylate | 149 | $906 | $6 |
| Furosemide | 95 | $852 | $9 |
| Potassium Chloride | 24 | $850 | $35 |
| Losartan | 87 | $794 | $9 |
| Rosuvastatin | 13 | $756 | $58 |
| Lisinopril | 121 | $591 | $5 |
| Diltiazem | 15 | $553 | $37 |
| Metoprolol | 77 | $473 | $6 |
| Carvedilol | 58 | $410 | $7 |
| Hydrochlorothiazide | 95 | $404 | $4 |
| Verapamil | 13 | $356 | $27 |
| Olmesartan Medoxomil | 12 | $286 | $24 |
| Pravastatin | 16 | $270 | $17 |
| Clonidine | 22 | $257 | $12 |
| Simvastatin | 31 | $252 | $8 |
| Atenolol | 21 | $233 | $11 |
| Cephalexin | 35 | $78 | $2 |
2018: 34 drugs
| Eliquis | 83 | $42,095 | $507 |
| Xarelto | 37 | $18,638 | $504 |
| Pradaxa | 21 | $11,728 | $558 |
| Brilinta | 13 | $4,502 | $346 |
| Metoprolol | 169 | $3,761 | $22 |
| Midodrine | 37 | $3,382 | $91 |
| Warfarin | 226 | $3,265 | $14 |
| Digox | 28 | $1,982 | $71 |
| Amiodarone | 79 | $1,750 | $22 |
| Flecainide Acetate | 26 | $1,578 | $61 |
| Ezetimibe | 23 | $1,455 | $63 |
| Sotalol | 65 | $1,244 | $19 |
| Valsartan | 26 | $1,129 | $43 |
| Isosorbide Mononitrate Er | 55 | $1,072 | $19 |
| Atorvastatin | 69 | $956 | $14 |
| Clopidogrel | 82 | $758 | $9 |
| Digoxin | 22 | $678 | $31 |
| Amlodipine Besylate | 74 | $657 | $9 |
| Potassium Chloride | 20 | $583 | $29 |
| Metoprolol | 104 | $573 | $6 |
| Diltiazem | 12 | $557 | $46 |
| Furosemide | 73 | $546 | $7 |
| Cartia Xt | 16 | $545 | $34 |
| Diltiazem 24hr Er | 13 | $476 | $37 |
| Diltiazem 24hr Er (Cd) | 24 | $473 | $20 |
| Losartan | 70 | $421 | $6 |
| Carvedilol | 43 | $419 | $10 |
| Lisinopril | 60 | $308 | $5 |
| Pravastatin | 12 | $296 | $25 |
| Hydrochlorothiazide | 39 | $257 | $7 |
| Olmesartan Medoxomil | 13 | $224 | $17 |
| Atenolol | 22 | $156 | $7 |
| Simvastatin | 25 | $114 | $5 |
| Pantoprazole | 13 | $83 | $6 |
2017: 27 drugs
| Eliquis | 41 | $18,578 | $453 |
| Xarelto | 29 | $14,147 | $488 |
| Pradaxa | 17 | $6,736 | $396 |
| Brilinta | 12 | $3,914 | $326 |
| Metoprolol | 191 | $3,722 | $19 |
| Flecainide Acetate | 45 | $3,546 | $79 |
| Warfarin | 281 | $3,285 | $12 |
| Midodrine | 27 | $1,870 | $69 |
| Ezetimibe | 12 | $1,821 | $152 |
| Sotalol | 61 | $1,441 | $24 |
| Valsartan | 19 | $1,298 | $68 |
| Amiodarone | 73 | $1,213 | $17 |
| Diltiazem 24hr Er | 31 | $712 | $23 |
| Potassium Chloride | 23 | $610 | $27 |
| Clopidogrel | 58 | $492 | $8 |
| Metoprolol | 77 | $456 | $6 |
| Atorvastatin | 41 | $395 | $10 |
| Isosorbide Mononitrate Er | 16 | $362 | $23 |
| Furosemide | 67 | $348 | $5 |
| Amlodipine Besylate | 55 | $342 | $6 |
| Carvedilol | 38 | $331 | $9 |
| Lisinopril | 56 | $301 | $5 |
| Hydrochlorothiazide | 51 | $256 | $5 |
| Cartia Xt | 17 | $234 | $14 |
| Losartan | 32 | $205 | $6 |
| Simvastatin | 16 | $130 | $8 |
| Atenolol | 14 | $106 | $8 |
2016: 25 drugs
| Xarelto | 38 | $15,822 | $416 |
| Metoprolol | 154 | $3,466 | $23 |
| Warfarin | 268 | $3,038 | $11 |
| Zetia | 11 | $2,989 | $272 |
| Propafenone Hcl Er | 12 | $2,032 | $169 |
| Flecainide Acetate | 32 | $1,587 | $50 |
| Potassium Chloride | 16 | $1,586 | $99 |
| Valsartan | 22 | $1,066 | $48 |
| Amiodarone | 57 | $892 | $16 |
| Diltiazem 24hr Er | 17 | $619 | $36 |
| Sotalol | 43 | $536 | $12 |
| Clopidogrel | 46 | $347 | $8 |
| Metoprolol | 38 | $269 | $7 |
| Atenolol | 22 | $248 | $11 |
| Simvastatin | 20 | $246 | $12 |
| Isosorbide Mononitrate Er | 17 | $244 | $14 |
| Cartia Xt | 17 | $238 | $14 |
| Furosemide | 46 | $228 | $5 |
| Amlodipine Besylate | 25 | $226 | $9 |
| Lisinopril | 33 | $190 | $6 |
| Hydrochlorothiazide | 41 | $151 | $4 |
| Carvedilol | 18 | $139 | $8 |
| Losartan | 19 | $137 | $7 |
| Atorvastatin | 16 | $131 | $8 |
| Clonidine | 12 | $66 | $6 |
2015: 23 drugs
| Xarelto | 35 | $14,426 | $412 |
| Pradaxa | 30 | $10,462 | $349 |
| Metoprolol | 94 | $2,798 | $30 |
| Warfarin | 186 | $2,481 | $13 |
| Valsartan | 11 | $1,959 | $178 |
| Digox | 16 | $1,134 | $71 |
| Flecainide Acetate | 23 | $967 | $42 |
| Potassium Chloride | 14 | $793 | $57 |
| Amiodarone | 36 | $749 | $21 |
| Sotalol | 38 | $665 | $17 |
| Losartan | 36 | $443 | $12 |
| Isosorbide Mononitrate Er | 24 | $314 | $13 |
| Cartia Xt | 11 | $285 | $26 |
| Clopidogrel | 33 | $260 | $8 |
| Amlodipine Besylate | 30 | $244 | $8 |
| Atenolol | 24 | $237 | $10 |
| Carvedilol | 28 | $232 | $8 |
| Furosemide | 26 | $226 | $9 |
| Metoprolol | 33 | $185 | $6 |
| Simvastatin | 19 | $168 | $9 |
| Hydrochlorothiazide | 25 | $128 | $5 |
| Lisinopril | 17 | $105 | $6 |
| Clonidine | 12 | $65 | $5 |
2014: 24 drugs
| Xarelto | 38 | $18,927 | $498 |
| Pradaxa | 19 | $6,108 | $321 |
| Multaq | 12 | $5,841 | $487 |
| Metoprolol | 74 | $2,488 | $34 |
| Warfarin | 146 | $1,927 | $13 |
| Digox | 23 | $1,368 | $59 |
| Midodrine | 12 | $1,057 | $88 |
| Amiodarone | 46 | $886 | $19 |
| Sotalol | 32 | $827 | $26 |
| Atorvastatin | 26 | $785 | $30 |
| Clopidogrel | 44 | $633 | $14 |
| Potassium Chloride | 15 | $470 | $31 |
| Carvedilol | 31 | $467 | $15 |
| Amlodipine Besylate | 62 | $425 | $7 |
| Flecainide Acetate | 13 | $416 | $32 |
| Cartia Xt | 12 | $413 | $34 |
| Losartan | 19 | $406 | $21 |
| Furosemide | 29 | $313 | $11 |
| Lisinopril | 22 | $291 | $13 |
| Isosorbide Mononitrate Er | 19 | $274 | $14 |
| Metoprolol | 30 | $180 | $6 |
| Simvastatin | 15 | $154 | $10 |
| Atenolol | 16 | $148 | $9 |
| Hydrochlorothiazide | 17 | $49 | $3 |
2013: 24 drugs
| Xarelto | 33 | $11,718 | $355 |
| Multaq | 26 | $8,135 | $313 |
| Pradaxa | 13 | $3,410 | $262 |
| Propafenone | 19 | $3,029 | $159 |
| Metoprolol | 58 | $2,194 | $38 |
| Warfarin | 122 | $2,037 | $17 |
| Clopidogrel | 42 | $1,368 | $33 |
| Atorvastatin | 32 | $1,084 | $34 |
| Diltiazem 24hr Cd | 16 | $973 | $61 |
| Amiodarone | 35 | $721 | $21 |
| Cartia Xt | 18 | $632 | $35 |
| Flecainide Acetate | 18 | $614 | $34 |
| Isosorbide Mononitrate Er | 42 | $557 | $13 |
| Carvedilol | 32 | $514 | $16 |
| Atenolol | 20 | $458 | $23 |
| Lisinopril | 31 | $452 | $15 |
| Potassium Chloride | 16 | $420 | $26 |
| Amlodipine Besylate | 31 | $381 | $12 |
| Furosemide | 43 | $362 | $8 |
| Metoprolol | 42 | $323 | $8 |
| Sotalol | 17 | $316 | $19 |
| Digox | 19 | $211 | $11 |
| Simvastatin | 13 | $194 | $15 |
| Torsemide | 12 | $141 | $12 |
Money from drug and device companies
$3,056 in 2025
| 2025 | 19 | 107 | None | $3,056 |
| 2024 | 19 | 125 | None | $2,592 |
| 2023 | 17 | 103 | None | $2,193 |
| 2022 | 15 | 109 | None | $4,061 |
| 2021 | 9 | 72 | $248 | $1,513 |
| 2020 | 9 | 36 | None | $589 |
| 2019 | 10 | 60 | $2,575 | $3,749 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik | Biomonitor | $1,020 | 19 payments
|
| Abbott Laboratories | Gallant | $331 | 13 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $322 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $263 | 15 payments
|
| Novo Nordisk | Wegovy | $249 | 7 payments
|
| Amgen | Repatha | $164 | 7 payments
|
See all 103 published payments
| Edwards Lifesciences | Meals · 2025-12-17 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-16 | Eliquis | $27 |
| Biotronik | Meals · 2025-12-13 | Acticor 7 Vr-T Dx | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-11 | Farxiga | $20 |
| Biosense Webster | Meals · 2025-12-05 | Carto 3 | $29 |
| Amgen | Meals · 2025-12-05 | Repatha | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-01 | Kerendia | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-25 | Farxiga | $21 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-11-14 | Lifevest | $14 |
| Novo Nordisk | Meals · 2025-11-13 | Wegovy | $22 |
| Abbott Laboratories | Meals · 2025-11-12 | Amplatzer Amulet | $21 |
| Abbott Laboratories | Meals · 2025-11-12 | Amplatzer Amulet | $32 |
| Biotronik | Meals · 2025-11-11 | Amvia Edge | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-06 | Farxiga | $25 |
| Biotronik | Meals · 2025-11-04 | Amvia Edge | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-29 | Kerendia | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-27 | Eliquis | $22 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-10-24 | Lifevest | $24 |
| Abbott Laboratories | Meals · 2025-10-23 | Assurity | $31 |
| Novo Nordisk | Meals · 2025-10-22 | Wegovy | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-20 | Jardiance | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-17 | Eliquis | $13 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-16 | Farxiga | $23 |
| Biotronik | Meals · 2025-10-14 | Amvia Edge | $26 |
| Biotronik | Meals · 2025-10-07 | Biomonitor | $18 |
| Novo Nordisk | Meals · 2025-09-30 | Wegovy | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-24 | Farxiga | $30 |
| Abbott Laboratories | Meals · 2025-09-24 | Assurity | $23 |
| Abbott Laboratories | Meals · 2025-09-24 | Gallant | $40 |
| Biotronik | Meals · 2025-09-23 | Amvia Edge | $39 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-22 | Kerendia | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-18 | Farxiga | $18 |
| Merck Sharp & Dohme | Meals · 2025-09-05 | Verquvo | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-04 | Eliquis | $28 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-03 | Jardiance | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-30 | Farxiga | $21 |
| Novo Nordisk | Meals · 2025-08-22 | Wegovy | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-18 | Kerendia | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-13 | Eliquis | $10 |
| Pfizer | Meals · 2025-08-13 | Eliquis | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-07 | Farxiga | $33 |
| BridgeBio Pharma | Meals · 2025-08-07 | Attruby | $30 |
| Biotronik | Meals · 2025-08-05 | Renamic Neo | $22 |
| Amgen | Meals · 2025-08-01 | Repatha | $20 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-07-30 | Lifevest | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-30 | Eliquis | $13 |
| Boston Scientific | Meals · 2025-07-29 | Watchman Flx | $21 |
| Abbott Laboratories | Meals · 2025-07-23 | Gallant | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Farxiga | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-14 | Eliquis | $22 |
| Merck Sharp & Dohme | Meals · 2025-07-11 | Verquvo | $20 |
| BridgeBio Pharma | Meals · 2025-07-09 | Attruby | $36 |
| Alnylam Pharmaceuticals | Meals · 2025-07-08 | Amvuttra | $32 |
| Biotronik | Meals · 2025-07-01 | Biomonitor | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-30 | Kerendia | $20 |
| Amgen | Meals · 2025-06-27 | Repatha | $29 |
| Abbott Laboratories | Meals · 2025-06-24 | Gallant | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-19 | Farxiga | $25 |
| Scpharmaceuticals | Meals · 2025-06-19 | Furoscix | $31 |
| Biotronik | Meals · 2025-06-03 | Biomonitor | $32 |
| Biotronik | Meals · 2025-05-30 | Biomonitor | $11 |
| Biotronik | Meals · 2025-05-30 | Biomonitor | $25 |
| Biotronik | Meals · 2025-05-30 | Biomonitor | $3 |
| Biotronik | Travel · 2025-05-22 | Biomonitor | $601 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-21 | Lifevest | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-16 | Camzyos | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-15 | Farxiga | $30 |
| Novo Nordisk | Meals · 2025-05-13 | Wegovy | $24 |
| Merck Sharp & Dohme | Meals · 2025-05-09 | Verquvo | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-05 | Jardiance | $25 |
| Abbott Laboratories | Meals · 2025-04-30 | Merlin@Home | $18 |
| Abbott Laboratories | Meals · 2025-04-30 | Gallant | $20 |
| Amgen | Meals · 2025-04-28 | Repatha | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-21 | Eliquis | $26 |
| Novo Nordisk | Meals · 2025-04-17 | Wegovy | $119 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-16 | Eliquis | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-08 | Farxiga | $29 |
| Abbott Laboratories | Meals · 2025-04-04 | Gallant | $19 |
| Amgen | Meals · 2025-03-31 | Repatha | $20 |
| Boston Scientific | Meals · 2025-03-24 | Watchman Flx | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-20 | Farxiga | $20 |
| Biotronik | Meals · 2025-03-18 | None | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-17 | Eliquis | $12 |
| Novo Nordisk | Meals · 2025-03-17 | Wegovy | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-10 | Camzyos | $23 |
| Merck Sharp & Dohme | Meals · 2025-03-07 | Verquvo | $15 |
| Biotronik | Meals · 2025-03-04 | Biomonitor | $37 |
| Amgen | Meals · 2025-02-26 | Repatha | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-24 | Camzyos | $6 |
| Abbott Laboratories | Meals · 2025-02-21 | Merlin@Home | $19 |
| Abbott Laboratories | Meals · 2025-02-19 | Gallant | $36 |
| Novartis Pharmaceuticals | Meals · 2025-02-10 | Leqvio | $29 |
| Abbott Laboratories | Meals · 2025-02-07 | Assurity | $21 |
| Biotronik | Meals · 2025-02-04 | Biomonitor | $32 |
| Amgen | Meals · 2025-01-31 | Repatha | $29 |
| Pfizer | Meals · 2025-01-27 | Eliquis | $23 |
| Heartflow | Meals · 2025-01-23 | Ffrct | $45 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-22 | Camzyos | $7 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-22 | Camzyos | $17 |
| Biotronik | Meals · 2025-01-21 | Biomonitor | $43 |
| Edwards Lifesciences | Meals · 2025-01-20 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $15 |
| Biotronik | Meals · 2025-01-09 | Biomonitor | $5 |
| Biotronik | Meals · 2025-01-07 | Biomonitor | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,592
| AstraZeneca Pharmaceuticals LP | Farxiga | $448 | 19 payments
|
| Abbott Laboratories | Jot Dx | $424 | 22 payments
|
| Biotronik | Biomonitor | $226 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $226 | 15 payments
|
| Amgen | Repatha | $219 | 10 payments
|
| Novo Nordisk | Ozempic | $167 | 4 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $154 | 8 payments
|
| Novartis Pharmaceuticals | Entresto | $150 | 8 payments
|
| Merck Sharp & Dohme | Verquvo | $107 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $89 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $64 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $63 | 2 payments
|
| Boston Scientific | Watchman Flx | $55 | 3 payments
|
| Lexicon Pharmaceuticals | None | $50 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $45 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $33 | 2 payments
|
| Pfizer | Eliquis | $29 | 2 payments
|
| Medtronic | Micra | $27 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $16 | 1 payment
|
2023: $2,193
| Abbott Laboratories | Jot Dx | $491 | 26 payments
|
| Biosense Webster | Carto 3 | $216 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $199 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $197 | 13 payments
|
| Janssen Pharmaceuticals | Xarelto | $187 | 8 payments
|
| Amgen | Repatha | $163 | 7 payments
|
| Merck Sharp & Dohme | Verquvo | $149 | 8 payments
|
| Novartis Pharmaceuticals | Leqvio | $101 | 3 payments
|
| Lexicon Pharmaceuticals | Inpefa | $91 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $91 | 4 payments
|
| Impulse Dynamics (USA) | Optimizer | $72 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $67 | 4 payments
|
| Pfizer | Eliquis | $58 | 3 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $54 | 2 payments
|
| Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor | $25 | 1 payment
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $17 | 1 payment
|
| Biotronik | Edora 8 Dr-T | $16 | 1 payment
|
2022: $4,061
| Medical Device Business Services | Carto 3 | $1,989 | 4 payments
|
| Abbott Laboratories | Assurity | $996 | 47 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $155 | 14 payments
|
| Amgen | Repatha | $144 | 6 payments
|
| Janssen Pharmaceuticals | Xarelto | $139 | 7 payments
|
| Biosense Webster | Carto 3 | $129 | 9 payments
|
| Impulse Dynamics (USA) | Optimizer | $117 | 3 payments
|
| Cardiva Medical | Cardiva Vascade 6/7f Vcs | $99 | 3 payments
|
| Pfizer | Eliquis | $58 | 4 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $48 | 2 payments
|
| Medtronic | Aquamantys(Tm) | $46 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $42 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $36 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $35 | 2 payments
|
| Biotronik | Edora 8 Dr-T | $29 | 2 payments
|
2021: $1,513
| Abbott Laboratories | Confirm Rx | $747 | 49 payments
|
| Biosense Webster | Carto 3 | $254 | 2 payments
|
| Biotronik | Edora | $170 | 5 payments
|
| Amgen | Repatha | $121 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $117 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $43 | 2 payments
|
| Medtronic | Reveal Linq | $33 | 2 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $17 | 1 payment
|
| Pfizer | Eliquis | $12 | 1 payment
|
2020: $589
| Abbott Laboratories | Merlin Connectivity and Remote | $208 | 20 payments
|
| Amgen | Repatha | $118 | 4 payments
|
| Biosense Webster | Carto 3 System | $61 | 3 payments
|
| Medtronic Vascular | Micra | $58 | 3 payments
|
| Biotronik | None | $47 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $33 | 2 payments
|
| Philips Electronics North America | (7999) Src Undivided | $26 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $20 | 1 payment
|
| Lundbeck | Northera | $18 | 1 payment
|
2019: $3,749
| Biotronik | Iperia | $1,934 | 8 payments
|
| Abbott Laboratories | Confirm Rx | $1,176 | 16 payments
|
| Medtronic Vascular | Claria Mri | $157 | 1 payment
|
| Amgen | Repatha | $151 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $142 | 20 payments
|
| Janssen Pharmaceuticals | Xarelto | $74 | 4 payments
|
| Lundbeck | Northera | $46 | 2 payments
|
| Biosense Webster | Carto 3 System | $35 | 1 payment
|
| Regeneron Healthcare Solutions | Praluent | $22 | 1 payment
|
| Pfizer | Eliquis | $13 | 1 payment
|
Checkups this office reported
6 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 790 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 93%That's most of the people this applied to. | 202 |
| Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery PatientsAs Medicare defines this measure | 0% | 499 |
| Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk PatientsAs Medicare defines this measure | 0% | 499 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 100% | 1,810 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 899 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1104803048
- Licence
- CA C53436California C53436: Current · expires 2028-01-31
- Trained
- Johns Hopkins University School of Medicine, 1993
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Cardiology (207RC0000X)
- Mailing address
- 312 Lester Ct, Santa Clara, CA, 95051
- NPI first listed
- 2005-12-30
- NPI last updated
- 2018-02-09
This is when the NPI record was last certified, not a medical board exam.